Hemogenyx Pharmaceuticals Plc

LSE:HEMO Stock Report

Market Cap: UK£16.1m

Hemogenyx Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 5/6

Hemogenyx Pharmaceuticals has a total shareholder equity of £3.0M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £6.1M and £3.1M respectively.

Key information

0%

Debt to equity ratio

UK£0

Debt

Interest coverage ration/a
CashUK£1.64m
EquityUK£3.02m
Total liabilitiesUK£3.09m
Total assetsUK£6.12m

Recent financial health updates

Recent updates

Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?

Aug 21
Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?

Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?

May 04
Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?

We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully

Jan 06
We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully

Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?

Oct 09
Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?

Financial Position Analysis

Short Term Liabilities: HEMO's short term assets (£2.5M) exceed its short term liabilities (£564.3K).

Long Term Liabilities: HEMO's short term assets (£2.5M) do not cover its long term liabilities (£2.5M).


Debt to Equity History and Analysis

Debt Level: HEMO is debt free.

Reducing Debt: HEMO has no debt compared to 5 years ago when its debt to equity ratio was 415.7%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HEMO has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: HEMO is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies